Surgical excision of anal sac apocrine gland adenocarcinomas with and without adjunctive chemotherapy in dogs: 42 cases (2005-2011).

Objective-To identify variables associated with prognosis in dogs undergoing surgical excision of anal sac apocrine gland adenocarcinomas (ASACs) with and without adjunctive chemotherapy. Design-Retrospective case series. Animals-42 dogs with ASACs.

Single agent gemcitabine chemotherapy in dogs with spontaneously occurring lymphoma.

Background: Gemcitabine has been shown to be effective as a single agent in a variety of tumors including nonHodgkin's lymphoma. Its use in veterinary medicine has been limited and to date this drug has not been used as a first-line therapy in dogs with lymphoma.

Hypothesis: Gemcitabine as a single agent may be efficacious in dogs presented for the first time with lymphoma.

Carcinoma of the apocrine glands of the anal sac in dogs: 113 cases (1985-1995).

Objective: To characterize the signalment, clinical signs, biological behavior, and response to treatment of carcinoma of the apocrine glands of the anal sac in dogs.

Design: Retrospective study.

Animals: 113 dogs with histologically confirmed carcinoma of the apocrine glands of the anal sac.